Target intelligence / Profile preview

4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL)

Target
HPDL
Molecular classification
Enzyme, Iron-dependent dioxygenase, Oxidoreductase, Mitochondrial protein
01

Overview

4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL) is a mitochondrial iron-dependent enzyme, structurally related to 4-hydroxyphenylpyruvate dioxygenase but with distinctive, yet incompletely characterized, activity. HPDL localizes to the mitochondrial intermembrane space and is implicated in regulating mitochondrial respiration and cellular ATP production through glutamine metabolism. It plays an essential role in maintaining redox balance via a glutamine-dependent antioxidant pathway, and protects against oxidative stress. HPDL overexpression is associated with pancreatic cancer progression and poorer outcomes, while biallelic mutations in HPDL result in neurodegenerative conditions such as hereditary spastic paraplegia (SPG83). Though its exact substrate and enzymatic products remain undefined, HPDL's function is critical for cellular metabolism, redox homeostasis, and potentially for neuronal integrity and cell survival in disease.

Other names
4-hydroxyphenylpyruvate dioxygenase-like proteinHPDLGLOXD1HPD-like proteinMGC156684-HPPD-Lglyoxalase domain-containing protein 1NEDSWMASPG83
02

Mechanism of action

Not established drug mechanisms, but molecular function involves mitochondrial bioenergetics regulation and redox balance, especially via glutamine metabolism.

03

Biological functions

Mitochondrial bioenergeticsRegulation of ATP generation (glutamine-dependent)Redox homeostasis (antioxidative glutamine-dependent pathway)Possible involvement in apoptosis
04

Disease associations

Cancer (promotes pancreatic tumor cell proliferation and poor prognosis in pancreatic ductal adenocarcinoma)Neurodegenerative disease (e.g., spastic paraplegia 83, neurodevelopmental disorder with progressive spasticity)
05

Safety considerations

As a potential therapeutic target, mitochondrial and redox pathway targeting may risk affecting normal energy homeostasis and neuron viability
06

Biomarkers

Overexpression in pancreatic ductal adenocarcinoma associated with poor prognosis

Beyond the preview

Go deeper on 4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on 4-hydroxyphenylpyruvate dioxygenase-like protein (HPDL).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call